Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Tirzepatide dual GIP/GLP-1 mechanism consistently produces greater weight loss than semaglutide single GLP-1 activation in clinical trials
These conditions may require medical intervention
There is a growing interest in using GLP-1RAs as a therapeutic agent for the treatment of motivation and reward-related behavioral disorders
Bottom line Eli Lilly and Companys licensing deal for Hanmi Pharmaceuticalss sonefpeglutide adds a potentially differentiated GLP-2 therapy with total deal value reaching $1.26 billion
Expression of phospholipase C isozymes in human breast cancer and their clinical significance
Ischemic stroke and intestinal flora: an insight into brain-gut axis
US$ 29.65
US$ 21.11
US$ 22.14
US$ 24.74
US$ 23.73
US$ 23.48
US$ 29.28
US$ 24.75
US$ 20.21
